All In Biotech

Drug Trial Radar · NCT05569759

A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA)

A Randomized, Double-blind, Placebo-controlled, Phase 2a Study With Open-label Extension to Evaluate the Safety and Efficacy of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis

Last checked: Nov 20, 2026Latest source record: Jan 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

24

Actual

Start

May 23, 2023

Primary completion

Apr 30, 2025

Study completion Apr 30, 2025

Sponsor

Lead sponsor
Kezar Life Sciences, Inc.Industry
Sponsor type
Industry
First posted
Oct 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis received zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allowed participants to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.

Conditions

  • Autoimmune Hepatitis

Interventions

  • zetomipzomibDrug

    Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly

  • placeboDrug

    Subcutaneous injection of placebo

  • zetomipzomib in open-label extensionDrug

    Subcutaneous injection of zetomipzomib with a target dose of 60 mg weekly

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patients Who Achieved Complete Biochemical ResponseTime frame: Week 12, Week 16, Week 20, and Week 24
  2. The Safety and Tolerability of ZetomipzomibTime frame: Baseline through end of study visit (DBTP, Week 28 and OLE, Up to Week 24)
  3. Proportion of Participants Experiencing a Disease Flare Among the Participants Who Achieved a CR During the Double-blind Treatment PeriodTime frame: Start of open-label extension (OLE) period through End of Study (EOS) up to OLE Week 25

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona

    Phoenix, Arizona

  • Keck School of Medicine of USC

    Los Angeles, California

  • University of California, Los Angeles

    Los Angeles, California

  • Stanford Medicine

    Redwood City, California

  • California Pacific Medical Center

    San Francisco, California

  • University of California, San Francisco

    San Francisco, California

  • University of Colorado

    Aurora, Colorado

  • Yale University

    New Haven, Connecticut

  • Mayo Clinic Florida

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • Northwestern University

    Chicago, Illinois

  • Rush University

    Chicago, Illinois

  • Indiana University

    Indianapolis, Indiana

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • University of Michigan Medical Center

    Ann Arbor, Michigan

  • Washington University School of Medicine

    St Louis, Missouri

  • Northwell Health Center for Liver Disease and Transplantation

    Manhasset, New York

  • New York University Langone Health/Grossman School of Medicine

    New York, New York

  • Duke University Medical Center

    Durham, North Carolina

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Virginia Commonwealth University

    Richmond, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.